NRSNW | NeuroSense Therapeutics Ltd. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.1400 - 0.1700
52 Week Range	0.1400 - 0.1700
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	2,684
Average Volume	N/A
Shares Outstanding	144,734,480
Market Cap	24,604,862
Sector	Healthcare
Industry	Biotechnology
IPO Date	N/A

Valuation
Profitability
Growth
Health
P/E Ratio	-0.18
Forward P/E Ratio	N/A
EPS	-0.94
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	18
Country	Israel
Website	NRSNW

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel. Its lead product candidate is PrimeC, a novel oral formulation for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline product candidates include StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

NRSNW's peers: NRSN, KTTAW, GOVXW, NLSPW, CINGW, NXGLW

*Chart delayed

Analyzing fundamentals for NRSNW we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see NRSNW Fundamentals page.

Watching at NRSNW technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on NRSNW Technicals page.